Abstract
Transfusion medicine is an increasingly important cross-disciplinary field that pertains to clinical hematology and diagnostic pathology, as well as to surgery, obstetrics and gynecology, internal medicine, pediatrics, and emergency medicine.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
AABB. Standards for blood banks and transfusion services. 29th ed. Bethesda: AABB Press; 2014.
Anstee DJ. Red cell genotyping and the future of pretransfusion testing. Blood. 2009;114:248–56.
Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion. 2002;42(1):37–43.
Benjamin RJ, McLaughlin LS. Plasma components: properties, differences, and uses. Transfusion. 2012;52 Suppl 1:9S–19.
Cid J, Lozano M, Ziman A, et al. Biomedical excellence for safer transfusion collaborative. Low frequency of anti-D alloimmunization following D+ platelet transfusion: the anti-D alloimmunization after D-incompatible platelet transfusions (ADAPT) study. Br J Haematol. 2015;168(4):598–603.
Daniel-Johnson J, Schwartz J. How do I approach ABO-incompatible hematopoietic progenitor cell transplantation? Transfusion. 2011;51(6):1143–9.
European Committee on Blood Transfusion. Guide to the preparation, use and quality assurance of blood components. 16th ed. Strasbourg: European Directorate for the Quality of Medicines; 2010.
Fritz RD, Forkner Jr CE, Freireich EJ, Frei E 3rd, Thomas LB. The association of fatal intracranial hemorrhage and blastic crisis in patients with acute leukemia. N Engl J Med. 1959;261:59–64.
Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. TRALI Consensus Panel. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev. 2005;19(1):2–31.
Han T, Stutzman L, Cohen E, Kim U. Effect of platelet transfusion on hemorrhage in patients with acute leukemia. An autopsy study. Cancer. 1966;19:1937–42.
Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142(3):348–60.
Holland LL, Foster TM, Marlar RA, Brooks JP. Fresh frozen plasma is ineffective for correcting minimally elevated international normalized ratios. Transfusion. 2005;45(7):1234–5.
Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205–13.
Norton A, Allen DL, Murphy MF. Review: platelet alloantigens and antibodies and their clinical significance. Immunohematology. 2004;20(2):89–102.
Novotny VM. Prevention and management of platelet transfusion refractoriness. Vox Sang. 1999;76(1):1–13.
O’Brien KL, Haspel RL, Uhl L. Anti-D alloimmunization after D-incompatible platelet transfusions: a 14-year single-institution retrospective review. Transfusion. 2014;54(3):650–4.
Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11–9.
Pfuntner A, Wier LM, Stocks C. Most frequent procedures performed in U.S. Hospitals, 2010. Rockville: Agency for Healthcare Research and Quality; 2013. http://hcup-us.ahrq.gov/reports/statbriefs/sb149.pdf. Accessed 25 Nov 2014.
Quillen K, et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica. 2009;94(12):1661–8.
Seftel MD, Growe GH, Petraszko T, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood. 2004;103(1):333–9. Seftel MD, Growe GH, Petraszko T, et al.
Shirey RS, Boyd JS, Parwani AV, Tanz WS, Ness PM, King KE. Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management. Transfusion. 2002;42(11):1435–41.
Slichter SJ, et al. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med. 1997;337(26):1861–9.
Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362:600–13.
Storch EK, Hillyer CD, Shaz BH. Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies. Blood. 2014;124(12):1868–72.
Uhlmann EJ, Shenoy S, Goodnough LT. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion. Transfusion. 2014;54(2):384–8.
Winer ES, Safran H, Karaszewska B, et al. Safety and efficacy of eltrombopag versus placebo for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors receiving gemcitabine-based chemotherapy: a phase I study. J Clin Oncol 30, 2012;(supple):abstr 9117.
Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033–48.
Yazer M. The how’s and why’s of evidence based plasma therapy. Korean J Hematol. 2010;45:152–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
West, K.A., Cantilena, C. (2016). Transfusion Support: Indications, Efficacy, and Complications. In: Abutalib, S., Connors, J., Ragni, M. (eds) Nonmalignant Hematology. Springer, Cham. https://doi.org/10.1007/978-3-319-30352-9_59
Download citation
DOI: https://doi.org/10.1007/978-3-319-30352-9_59
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-30350-5
Online ISBN: 978-3-319-30352-9
eBook Packages: MedicineMedicine (R0)